Founders
The four founders of SSTI hold faculty positions in major medical centers nationwide and have considerable expertise in the Wnt, Notch, and Myc pathways. As a group, the founders have many decades of experience in cancer research, raised tens of millions of dollars in grant support, and have eight patents filed or pending covering both lead-compounds and novel drug targets relevant to cancer therapeutics.
Anthony J. Capobianco, Ph.D.
President
Dr. Anthony Capobianco is a Professor and Director of the Molecular Oncology Program in the Dewitt Daughtry Department of Surgery, at the University of Miami Miller School of Medicine. Dr. Capobianco’s lab was among the first to characterize the role of Notch signaling in cancer. His current research focuses on novel points of therapeutic intervention within the Notch signaling network. Dr. Capobianco received his Ph.D. degree from Boston University and was a postdoctoral fellow at UCSF.
Ethan Lee, M.D.-Ph.D.
Dr. Ethan Lee is a Professor in Cell & Developmental Biology, Cancer Biology, and Pharmacology at Vanderbilt University. His lab focuses on understanding mechanisms of Wnt signaling and the development of novel approaches to target this pathway. Dr. Lee received his M.D. and Ph.D. degrees from the University of Texas Southwestern Medical Center, followed by postdoctoral training at Harvard Medical School.
David J. Robbins, Ph.D.
Dr. David Robbins is a Professor and Endowed Chair in Experimental Therapeutics at Georgetown University. His research is focused on elucidating the roles Wnt and Sonic hedgehog (Shh) signaling pathways play in cancers, such as colorectal cancer and medulloblastoma. Dr. Robbins has served on the editorial boards of the Journal of Biological Chemistry, Current Cancer Therapy Reviews, and Cancer Research. He received his Ph.D. degree from UT Southwestern in Pharmacology, and completed postdoctoral training at UCSF.
William A. Weiss M.D.-Ph.D.
Dr. William Weiss is a Professor of Neurology, Pediatrics, and Neurological Surgery, at the University of California, San Francisco CA. He is an expert on developmental therapeutics, focusing on Myc, kinase biology, and in vivo models of cancer. Dr. Weiss co-leads the Pediatric Malignancies Program within UCSF’s Helen Diller Family Comprehensive Cancer Center, is a senior editor at Cancer Research, and is associate editor of Neuro-Oncology and of Molecular and Cellular Biology. Dr. Weiss received his M.D. and Ph.D. degrees from the Stanford University School of Medicine, and performed postdoctoral training at UCSF. He completed his clinical training in pediatrics at Boston Children’s Hospital, and in neurology at UCSF.
